Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(ALXN, CLNO, PWRM, IPCM, PETM) Stock in Focus by Stock-PR.com

Stock-PR Reporting

stockpr_logo-site

 

FREE Daily Stock Alerts From Stock-PR.com

chartstockalert

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced that Vikas Sinha, Chief Financial Officer of Alexion Pharmaceuticals, will present at the Wells Fargo Securities Healthcare Conference in Boston at 3:30 p.m., Eastern on Wednesday, June 22, 2011. An audio webcast of Mr. Sinha's remarks will be available live. You can access the webcast at: www.alexionpharma.com. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.

********************

http://pennyomega.com/img/clno.jpg Cleantech Transit Inc. (OTCPK:CLNO)

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (
www.phoenixenergy.net). This project can generate shareholder returns as well benefit the Company's manufacturing clients worldwide.

Cleantech Transit, Inc. is pleased to announce it has completed an agreement whereby it can earn a larger ownership percentage in the 500 KW bio mass Merced Project than previously announced.

Cleantech can now earn in up to 40% of the Merced Project up from the original 25% the Company announced. The 40% ownership stake will be based on the total cost incurred to the Project to date, in addition Cleantech can invest the in the Series B shares of Phoenix Energy equal to or greater to the direct investment made in 500 KW project.

An approach that may increase the use of biomass energy in the short term is to mix it with coal and burn it at a power plant designed for coal-a process known as "co-firing." Through gasification, biomass can also be co-fired at natural gas-powered plants. The benefits associated with biomass co-firing can include lower operating costs, reductions of harmful emissions like sulfur and mercury, greater energy security and, with the use of beneficial biomass, lower carbon emissions. Co-firing is also one of the more economically viable ways to increase biomass power generation today, since it can be done with modifications to existing facilities.

Please visit Cleantech Transit, Inc. website www.cleantechtransitinc.com.

*************

power3 Power3 Medical Products, Inc. (OTC:PWRM)

Power3 Medical Products, Inc.
is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

The NuroPro Blood Test is Power3's medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

ALS causes weakness with a wide range of disabilities. Eventually, all muscles under voluntary control are affected, and patients lose their strength and the ability to move their arms, legs, and body. Although the disease usually does not impair a person's mind or intelligence, several recent studies suggest that some ALS patients may have alterations in cognitive functions such as depression and problems with decision-making and memory. ALS does not affect a person's ability to see, smell, taste, hear, or recognize touch.

Please visit Power3 Medical Products, Inc website http://www.power3medical.com.

********************

IPC The Hospitalist Company, Inc. (Nasdaq:IPCM), a leading national physician group practice company, announced that Patrick G. Hays, 68, has resigned from its Board of Directors, became effective June 15, 2011, for health reasons. Hays retired from his former position as President and Chief Executive Officer of the Blue Cross Blue Shield Association in 2000.

IPC The Hospitalist Company, Inc., is a leading physician group practice company focused on the delivery of hospitalist medicine and related facility-based services. For more information, visit the IPC website at
www.hospitalist.com.

********************

PetSmart, Inc. (NASDAQ:PETM), the leader in pet specialty retail, announced the Board of Directors' approval to increase its quarterly dividend by 12% from $0.125 to $0.14 per share beginning in the second quarter of fiscal 2011. The Board of Directors also authorized a new $450 million share purchase program. This new share purchase program will commence on August 1, 2011, and continue until January 2013, and will replace any unused amount remaining under the June 2010 share purchase program as of the commencement date. "We believe the stability and predictability of our cash flow demonstrates the continued strength of our business," said Bob Moran, President and Chief Executive Officer. "Creating shareholder value remains a priority and we intend to manage our capital effectively by reinvesting in our business and returning excess capital to our shareholders." The dividend of $0.14 will be paid on August 12, 2011 to stockholders of record at the close of business on July 29, 2011. This is equivalent to an annual rate of $0.56 per share.

PetSmart, Inc., together with its subsidiaries, operates as a specialty retailer of products, services, and solutions for pets in North America. T PetSmart, Inc. was founded in 1986 and is based in Phoenix, Arizona.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates receiving 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (OTCPK:CLNO). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

http://stock-pr.com/img/stock-pr_buscard.jpg